Merger of Regeneration, Tutogen to result in RTI Biologics

By Lisa Kerner

Charlotte, N.C., Jan. 17 - Regeneration Technologies, Inc. and Tutogen Medical, Inc. plan to name the company resulting from their merger RTI Biologics, Inc.

The new company's stock will trade on the Nasdaq Global Market under Regeneration's current symbol, "RTIX."

"Our new company name is centered around 'Biologics,' which can include a wide array of biological solutions," Regeneration president and chief executive officer Brian K. Hutchinson said in a company news release.

"These are areas that represent strong growth and great promise in health care. We feel it is important to begin this new endeavor with a fresh brand that better represents the strengths of both Regeneration and Tutogen," Hutchinson added.

RTI Biologics will continue to leverage the strengths of both the BioCleanse and Tutoplast brand names, according to the release.

Regeneration and Tutogen announced on Nov. 13 a definitive agreement to combine the two companies in a tax-free, stock-for-stock exchange. Under the terms of the merger agreement, Tutogen shareholders will receive 1.22 shares of newly issued RTI common stock in exchange for each share of Tutogen common stock they own.

Tutogen manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue.

Regeneration processes allograft and xenograft tissue into shaped implants for use in orthopedic and other surgeries. Both companies are based in Alachua, Fla.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.